BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ozbudak IH, Shilo K, Tavora F, Rassaei N, Chu WS, Fukuoka J, Jen J, Travis WD, Franks TJ. Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol 2009;22:633-8. [PMID: 19234439 DOI: 10.1038/modpathol.2009.6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chai L, Ying HF, Wu TT, Zhou SH, Bao YY, Yao HT, You QH. Clinical features and hypoxic marker expression of primary sinonasal and laryngeal small-cell neuroendocrine carcinoma: a small case series. World J Surg Oncol 2014;12:199. [PMID: 24980293 DOI: 10.1186/1477-7819-12-199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
2 Wu X, Wang L, Yang D, Qu M, Yang Y, Guo F, Han L, Xue J. Retracted : Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF‐β/PI3K‐AKT‐mTOR signaling pathway. J Cell Biochem 2018;119:2356-67. [DOI: 10.1002/jcb.26399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
3 Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Virchows Arch 2013;462:83-93. [DOI: 10.1007/s00428-012-1344-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
4 Herrera-martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer 2019;26:R157-79. [DOI: 10.1530/erc-18-0354] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
5 Cakir M, Grossman A. The molecular pathogenesis and management of bronchial carcinoids. Expert Opinion on Therapeutic Targets 2011;15:457-91. [DOI: 10.1517/14728222.2011.555403] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
6 Smeland E, Kilvaer TK, Sorbye S, Valkov A, Andersen S, Bremnes RM, Busund LT, Donnem T. Prognostic impacts of hypoxic markers in soft tissue sarcoma. Sarcoma 2012;2012:541650. [PMID: 22454562 DOI: 10.1155/2012/541650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
7 Jiang Y, Hou G, Cheng W. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e14769. [PMID: 30855482 DOI: 10.1097/MD.0000000000014769] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
8 Obaid M, Udden SMN, Alluri P, Mandal SS. LncRNA HOTAIR regulates glucose transporter Glut1 expression and glucose uptake in macrophages during inflammation. Sci Rep 2021;11:232. [PMID: 33420270 DOI: 10.1038/s41598-020-80291-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Sommermann TG, O'Neill K, Plas DR, Cahir-McFarland E. IKKβ and NF-κB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res. 2011;71:7291-7300. [PMID: 21987722 DOI: 10.1158/0008-5472.can-11-1715] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
10 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Wang KR, Jia YJ, Zhou SH, Wang QY, Bao YY, Feng ZY, Yao HT, Fan J. Cutaneous and Subcutaneous Metastases From Atypical Laryngeal Carcinoids: Case Report and Review of the Literature. Medicine (Baltimore) 2016;95:e2796. [PMID: 26886629 DOI: 10.1097/MD.0000000000002796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol 2013;20:3892-8. [PMID: 23800898 DOI: 10.1245/s10434-013-3077-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
13 Basturk O, Singh R, Kaygusuz E, Balci S, Dursun N, Culhaci N, Adsay NV. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas. 2011;40:187-192. [PMID: 21206329 DOI: 10.1097/mpa.0b013e318201c935] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
14 Fujino M, Aishima S, Shindo K, Oda Y, Morimatsu K, Tsutsumi K, Otsuka T, Tanaka M, Oda Y. Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors. Oncol Lett 2016;12:3337-43. [PMID: 27900001 DOI: 10.3892/ol.2016.5092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
15 Romero-Garcia S, Lopez-Gonzalez JS, Báez-Viveros JL, Aguilar-Cazares D, Prado-Garcia H. Tumor cell metabolism: an integral view. Cancer Biol Ther 2011;12:939-48. [PMID: 22057267 DOI: 10.4161/cbt.12.11.18140] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 8.6] [Reference Citation Analysis]
16 Benzerdjeb N, Berna P, Sevestre H. GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors?: Reflection of proliferative activity. Pathol Int 2017;67:32-6. [DOI: 10.1111/pin.12486] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
17 Zhao ZX, Lu LW, Qiu J, Li QP, Xu F, Liu BJ, Dong JC, Gong WY. Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget 2018;9:2728-38. [PMID: 29416806 DOI: 10.18632/oncotarget.18964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
18 Gkika E, Benndorf M, Oerther B, Mohammad F, Beitinger S, Adebahr S, Carles M, Schimek-Jasch T, Zamboglou C, Frye BC, Bamberg F, Waller CF, Werner M, Grosu AL, Nestle U, Kayser G. Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer. Front Oncol 2020;10:1161. [PMID: 32903606 DOI: 10.3389/fonc.2020.01161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Tatci E, Ozmen O, Gokcek A, Biner IU, Ozaydin E, Kaya S, Arslan N. 18F-FDG PET/CT rarely provides additional information other than primary tumor detection in patients with pulmonary carcinoid tumors. Ann Thorac Med 2014;9:227-31. [PMID: 25276242 DOI: 10.4103/1817-1737.140134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]